ERS Genomics signs CRISPR patent deal on industrial applications
ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
1 November 2018 The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.
20 September 2018 ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
7 March 2018 The European Patent Office has granted a second CRISPR/Cas9 patent to a specialist genomics company, one month after revoking the Broad Institute of Harvard and MIT’s patent relating to the technology.